Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2015 16:00 ET | Source: Aravive, Inc.

Versartis Appoints Jay Shepard as President and Chief Executive Officer

MENLO PARK, Calif., May 6, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing VRS-317, a novel, long-acting form of recombinant...
April 13, 2015 08:30 ET | Source: Aravive, Inc.

Versartis Initiates Phase 2/3 Trial of VRS-317 in Japan for Children With Growth Hormone Deficiency

MENLO PARK, Calif., April 13, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human...
March 06, 2015 13:30 ET | Source: Aravive, Inc.

Versartis Presents 12-Month Data for VRS-317 at Late-Breaker Session at Endocrine Society's Annual Meeting

MENLO PARK, Calif., March 6, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human...
March 04, 2015 08:30 ET | Source: Aravive, Inc.

Versartis to Present at the Barclays Global Healthcare Conference

MENLO PARK, Calif., March 4, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human...
February 23, 2015 16:05 ET | Source: Aravive, Inc.

Versartis to Present at the Cowen and Company 35th Annual Health Care Conference

MENLO PARK, Calif., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human...
February 12, 2015 16:51 ET | Source: Aravive, Inc.

Versartis Reports Fourth Quarter and Full Year 2014 Financial Results

MENLO PARK, Calif., Feb. 12, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human...
February 02, 2015 16:05 ET | Source: Aravive, Inc.

Versartis to Present at the 2015 BIO CEO & Investor Conference

MENLO PARK, Calif., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human...
January 21, 2015 20:44 ET | Source: Aravive, Inc.

Versartis Announces Pricing of Follow-On Offering

MENLO PARK, Calif., Jan. 21, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company, today announced the pricing of an underwritten public offering...
January 20, 2015 06:10 ET | Source: Aravive, Inc.

Versartis Announces Proposed Offering of Common Stock

MENLO PARK, Calif., Jan. 20, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company, today announced that it has commenced an underwritten public...
January 08, 2015 08:30 ET | Source: Aravive, Inc.

Versartis Initiates Global Phase 3 Study of VRS-317 in Children With Growth Hormone Deficiency

MENLO PARK, Calif., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human...